Table 87Research Recommendation Statements

CriterionExplanation
PopulationPeople with a diagnosis of cystic fibrosis with respiratory symptoms
InterventionOnce daily dornase alfa (2.5 mg)
ComparatorsReduced dosing frequency of dornase alfa, including alternate day dornase alfa (2.5 mg)
Outcomes
  • Hospitalisations, change in frequency
  • Pulmonary exacerbations, change in frequency and severity
  • Lung function (FEV1, FVC)
  • Quality of Life (using a validated tool, such CFQ-R or CF-QOL)
  • Patient preference
  • Adverse events
  • Resource use
  • Unit costs
Study designMulticentre RCT
TimeframeFive years of randomisation and 5 year of follow up, providing recruitment numbers are sufficient to achieve population numbers of sufficient size to answer the research question.

From: 9, Pulmonary monitoring, assessment and management

Cover of Cystic Fibrosis
Cystic Fibrosis: Diagnosis and management.
NICE Guideline, No. 78.
National Guideline Alliance (UK).
Copyright © NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.